Search
Home
Latest
News
North America
Europe
Asia
Middle East
Global
Fortune 500
Fortune 500 U.S.
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Great Place To Work
Analytics
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
Home
Latest
Latest
News
North America
Europe
Asia
Middle East
Global
Fortune 500
Fortune 500
Fortune 500 U.S.
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Finance
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Rankings
Great Place To Work
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
Viren Vaghela
Stay informed with Viren Vaghela’s coverage and analysis for Fortune.
Health
AstraZeneca-Oxford COVID vaccine could get U.K. approval as soon as this week
By
Viren Vaghela
,
Thomas Penny
, and others
Finance
COVID put electronic trading to the test. It’s never buckled, Goldman Sachs says
By
Viren Vaghela
and
Bloomberg
Finance
In London, a Europe-heavy stock exchange is facing down Brexit
By
Silla Brush
,
Viren Vaghela
, and others
International
Banks are moving $1.6 trillion in assets out of the U.K. ahead of Brexit cutoff
By
Bloomberg
and
Viren Vaghela
Finance
London’s LSE Formally Rejects Hong Kong Exchange’s Surprise $37 Billion Bid
By
Viren Vaghela
and
Bloomberg
International
London Stock Exchange Places $27 Billion Bet on a Data-Driven Future
By
Viren Vaghela
and
Bloomberg